Clinical Trials Directory

Trials / Unknown

UnknownNCT01170195

Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
F&C Licorice Ltd · Academic / Other
Sex
Female
Age
45 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The purpose of the proposed study is to test the effect of Licorice Root Extract- Licogen on postmenopausal symptoms in postmenopausal women. Specifically, the study will also test the effect of the licorice extract on vaginal dryness.

Detailed description

The estrogenic properties of glabridin, the major isoflavan in licorice root, were tested in view of the resemblance of its structure and lipophilicity to those of estradiol. The results indicate that glabridin is a phytoestrogen, binding to the human estrogen receptor and stimulating creatine kinase activity in rat uterus, epiphyseal cartilage, diaphyseal bone, aorta, and left ventricle of the heart. The stimulatory effects of 2.5-25 mg/animal glabridin were similar to those of 5 mg/animal estradiol. Chemical modification of glabridin showed that the position of the hydroxyl groups has a significant role in binding to the human estrogen receptor and in proliferation-inducing activity. Glabridin was found to be three to four times more active than 2\*-O-methylglabridin and 4\*-O-methylglabridin, and both derivatives were more active than 2\*,4\*- O-methylglabridin. The effect of increasing concentrations of glabridin on the growth of breast tumor cells was biphasic. Glabridin showed an estrogen receptor-dependent, growth-promoting effect at low concentrations (10 nM-10 mM) and estrogen receptor-independent antiproliferative activity at concentrations of \>15 mM. This is the first study to indicate that isoflavans have estrogen-like activities. Glabridin and its derivatives exhibited varying degrees of estrogen receptor agonism in different tests and demonstrated growth-inhibitory actions on breast cancer cells.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTCalmera-Licorice Root Extract (Licogen)100 mg per day

Timeline

Start date
2010-09-01
Primary completion
2011-09-01
Completion
2011-09-01
First posted
2010-07-27
Last updated
2010-07-27

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01170195. Inclusion in this directory is not an endorsement.